PuSH - Publication Server of Helmholtz Zentrum München

93 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
1.
Li, M.* et al.: Induction of porcine-specific regulatory T cells with high specificity and expression of IL-10 and TGF-1 using baboon-derived tolerogenic dendritic cells. Xenotransplantation 25:e12355 (2018)
2.
Li, M.* ; Eckl, J. ; Geiger, C. ; Schendel, D.J. & Pohla, H.: A novel and effective method to generate human porcine-specific regulatory T cells with high expression of IL-10, TGF-β1 and IL-35. Sci. Rep. 7:3974 (2017)
3.
Lorenz, F.K.* et al.: Unbiased identification of T-cell receptors Targeting immunodominant peptide-MHC complexes for T-cell receptor immunotherapy. Hum. Gene Ther. 28, 1158-1168 (2017)
4.
Bigalke, I.* et al.: A new generation of dendritic cells to improve cancer therapy shows prolonged progression-free survival in patients with solid tumors. Cancer Res. 75:2516 (2015)
5.
Dargel, C. et al.: T cells engineered to express a T-cell receptor specific for glypican-3 to recognize and kill hepatoma cells in vitro and in mice. Gastroenterology 149, 1042-1052 (2015)
6.
Haase, K.* ; Raffegerst, S.H. ; Schendel, D.J. & Frishman, D.: Expitope: A web server for epitope expression. Bioinformatics 31, 1854-1856 (2015)
7.
Kobold, S.* et al.: Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer. J. Natl. Cancer Inst. 107:dju364 (2015)
8.
Lichtenegger, F.S. et al.: Next-generation dendritic cells for immunotherapy of acute myeloid leukemia. Ann. Hematol. 94, S53 (2015)
9.
Lorenz, F.K.* et al.: Codon optimization of the human papillomavirus E7 oncogene induces a CD8+ T cell response to a cryptic epitope not harbored by wild-type E7. PLoS ONE 10:e0121633 (2015)
10.
Schnorfeil, F.M. et al.: Vaccination with next-generation dendritic cells for aml postremission therapy induces antigen-specific T cell responses. Eur. J. Cancer 51, S8 (2015)
11.
Schnorfeil, F.M. et al.: Dendritic cell vaccination in postremission therapy of aml: Results of a clinical phase i trial and of preclinical studies testing combinatorial approaches. Haematologica 100, 287 (2015)
12.
Anderson, K.* et al.: Third generation autologous myeloid-derived dendritic cells developed from patients with CMML and MDS demonstrate phenotypic properties of mature functional dendritic cells. Cytotherapy 16, S24-S25 (2014)
13.
Bigalke, I.* et al.: Vaccination with a new generation of fast dendritic cells transfected with mRNA from hTERT, survivin and autologous tumor mount strong immune responses and prolong survival. Blood 124 (2014)
14.
Kobold, S.* et al.: Bispecific T cell recruiting antibody enhances anti-tumor activity of adoptive T cell transfer. Oncol. Res. Treat. 37, 239 (2014)
15.
Lichtenegger, F.S.* et al.: Next-generation dendritic cell vaccination as postremission therapy for AML patients with a non-favorable risk profile. Haematologica 99, 435-436 (2014)
16.
Lichtenegger, F.S. et al.: Next-generation dendritic cell vaccination as postremission therapy for AML patients with a non-favorable risk profile. Oncol. Res. Treat. 37, 310 (2014)
17.
Pinto, S.* et al.: Misinitiation of intrathymic MART-1 transcription and biased TCR usage explain the high frequency of MART-1-specific T cells. Eur. J. Immunol. 44, 2811-2821 (2014)
18.
Subklewe, M. et al.: New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. Cancer Immunol. Immunother. 63, 1093-1103 (2014)
19.
Gassenmaier, M.* et al.: CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis. Stem Cells 31, 1467-1476 (2013)
20.
Morgan, R.A.* et al.: Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133-151 (2013)